Very few people here understand your reference to the proposed...

Very few people here understand your reference to the proposed trial "protocol" so I won't bore them with your relentless clinging to the claim quoted below. You persisted in claiming that I was wrong in stating that CYP's proposed P2 trial in aGvHD was placebo controlled.
You said:
"you didn't even understand the trial has no placebo/saline."and"there IS NO true placebo"

Whereas Cynata's ASX announcement on 31/01/23 stated:

Phase 2 trial in aGvHD expected to commence by early 2023
As announced on 26 May 2022, the US FDA has cleared the Company’s IND application regarding a phase 2 clinical
trial to assess the efficacy of CYP-001 in patients suffering from aGvHD. This trial is on track with expectations to
commence in early 2023, with final start-up activities underway in concert with Contract Research Organisation
(CRO) IQVIA. The trial is designed to recruit approximately 60 patients across multiple clinical centres in the US,
Europe and Australia, who will be randomly allocated to receive either CYP-001 or a placebo, in addition to
corticosteroids. Results of the trial are expected in the second half of 2024.
The Company’s phase 1 trial in GvHD was a significant success, meeting all the safety and efficacy endpoints while
breaking ground as the world’s first completed clinical trial of an allogeneic iPSC-derived product.

I emphasised above your truly unbelievable inability to understand plain language. Also the fact that "early 2023" closes this week.

Anyway, this reply is only to relieve innocent bystanders of the wonderment at your diversion to a conversation from another board. At least it highlights your incompetence at understanding the announcements of your own favoured company. The truth is plain to all and I won't answer any more on this topic. And it risks being "off topic"